Skip to main content

Table 2 Comparison of the cumulative incidence rates of complications in the first, second and third doses of the vaccination in children

From: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran

Adverse events

Incidence (per 100 children) vaccine dose

P-value (1st and 2nd dose comparison)

P-value (2nd and 3rddose comparison)

1st dose (2 months)

N = 373

2nddose (4 months)

N = 372

3rddose (6 months)

N = 374

Swelling

79(0.21)

50(0.13)

48(0.12)

0.003

0.068

Redness

50(0.13)

30(0.08)

43(0.11)

0.026

0.679

Pain

190(0.5)

143(0.38)

62(0.43)

0.001

0.162

Mild fever

45(0.12)

33(0.08)

63(0.16)

0.068

<0.001

High fever

1(0.002)

0(0)

0(0)

0.388

NA

Drowsiness

83(0.22)

72(0.19)

70(0.18)

0.310

0.725

Anorexia

65(0.17)

51(0.13)

52(0.13)

0.126

1

Restlessness

35(0.06)

115(0.3)

119(0.31)

<0.001

0.766

Vomiting

16(0.04)

19(0.05)

17(0.04)

0.510

0.510

Long-term crying

24(0.06)

16(0.04)

22(0.05)

0.210

0.510

Encephalopathy

0(0)

0(0)

0(0)

NA

NA

Convulsion

0(0)

0(0)

0(0)

NA

NA

History of convulsion

0(0)

1(0.002)

2(0.005)

0.387

0.488

Family history of convulsion

0(0)

14(0.037)

6(0.016)

<0.001

0.074

  1. NA not applicable